# Kuur Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/kuur-therapeutics

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.kuurtx.com
- Total disclosed funding: $166M
- Latest round: Series C (Mar 15, 2017)
- Investors on record: 4

## About

Kuur Therapeutics, based in London, UK, specializes in innovative cell therapy solutions aimed at advancing cancer treatment and enhancing patient outcomes through cutting-edge technology.Founded in 2005, Kuur Therapeutics focuses on developing cell therapy solutions for cancer treatment. The company was acquired by Athenex, Inc. on May 4, 2021, for USD 185 mn from a consortium of investors including the Cancer Prevention & Research Institute of Texas. Gregg Sando serves as both CEO and Founder, bringing his extensive experience in therapeutic innovation to the organization.Kuur Therapeutics delivers advanced cell therapy solutions targeted at improving cancer treatment. Their core offerings include innovative therapeutics designed to enhance patient outcomes by harnessing the body’s immune system. These solutions address prevalent challenges in oncology, ultimately aiming to provide more effective treatments for patients diagnosed with various types of cancer.In 2018, Kuur Therapeutics reported an EBITDA of USD -970,573.7. The company generates revenue through structured models primarily including partnerships and collaborations that facilitate the integration of their therapeutic solutions into healthcare systems.Moving forward, Kuur Therapeutics plans to leverage the recent acquisition to enhance its cell therapy development capabilities. The funding from the USD 185 mn deal will be directed towards expanding R&D efforts, with a focus on launching new therapeutic products targeting unmet medical needs in oncology. The company aims to penetrate new markets, particularly within North America and Europe, by 2025 to broaden access to its innovative therapies.

## Funding rounds

- Series C, Mar 15, 2017, $74M — Invesco Perpetual, Touchstone Innovations, Woodford Patient Capital Trust
- Series B, Nov 24, 2014, $79M — Invesco Perpetual, Touchstone Innovations, Woodford Patient Capital Trust
- Series A, Jul 19, 2013, $13M — Wellcome Trust, Invesco Perpetual, Touchstone Innovations

## Investors

- Wellcome Trust — Series A
- Invesco Perpetual — Series A, Series B, Series C
- Touchstone Innovations (https://capitalatlas.ai/funds/touchstone-innovations) — Series A, Series B, Series C
- Woodford Patient Capital Trust — Series B, Series C